Growth for Lundbeck depression drugs

H. Lundbeck A/S recorded double-digit growth for its portfolio of new drugs for depression and schizophrenia in the first quarter, offsetting the loss of sales arising from generic competition. Group revenue for the quarter was DKK 4.6 billion (€615.4 million), up by 9% from a year earlier.

Full text available to subscribers only. Click here for information on subscribing to MedNous.